Business Wire

IL-LENOVO

Share
Motorola Expands Indigenous Languages Support With Addition of Ladin

Motorola and the Lenovo Foundation are committed to inclusion and smarter technology for all, and today we reaffirm this dedication with the expansion of our Indigenous Languages Support Initiative. As part of our ongoing efforts to raise awareness and empower Indigenous communities, Motorola is proud to announce the addition of Ladin, a minority language spoken in Italy’s Dolomites region (South of Tyrol), to the list of over 90 languages supported in our smartphones.

United Nations Educational, Scientific and Cultural Organization (UNESCO) estimates that one Indigenous language disappears every two weeks, resulting in the potential loss of around 3,000 unique languages by the end of the century. That’s why over the past three years, Motorola has been at the forefront of this mission, championing the revitalization of endangered languages across the globe.

With a focus on Europe for our latest phase of the Indigenous Languages Support Initiative, Motorola conducted extensive research to identify minority and endangered languages needing support. Among the languages considered, Ladin became a significant candidate, being one of the 12 officially recognized minority languages in Italy and one of three without a kinstate, or entity that is close to the region where their kin-groups reside. With only 30,000 speakers, UNESCO classifies Ladin as an endangered language.

"We've learned over the past few years that it is imperative that we work closely with the community of speakers and scholars that are passionate and committed to saving and promoting the language,” said Janine Oliveira, Executive Director of Software Globalization, Motorola. “This rang true for the Ladin community and made the decision to digitize the language in our devices easy."

Motorola worked alongside the Lenovo Foundation, and several translators and reviewers from the Ladin Institute, Micurá de Rü, led by Professor Paul Videsott, Professor for Romance Philology at the Free University of Bozen-Bolzano (UNIBZ). “This will definitely help Ladin and other minority languages to be more visible,” said Professor Videsott. “Smartphones are like the pencil of the 21st century, and having minority languages, including Ladin, in the motorola edge 50 series, has the same importance of having a language in a book.”

At Motorola, we know indigenous populations are interacting with mobile technology and are one of many diverse groups that make up our valued consumer base. It’s why we started the project, as we aim to preserve human heritage and the unique histories of Indigenous cultures while empowering future generations. But we also believe we have a responsibility to inspire others to do the same. Through June 2024, Motorola has open-sourced over 1 million translated indigenous words, allowing other companies to promote these languages through their interfaces, furthering revitalization efforts worldwide. Today, we’re also excited to share the latest version of our Hello Indigenous whitepaper written in partnership with Lenovo Foundation and UNESCO, serving as a blueprint for others to follow in their footsteps.

Ladin is the latest of several endangered languages that Motorola has added to its smartphone interface, including Kuvi and Kangri (spoken in regions of India), Cherokee (spoken in the United States), Kaingang (spoken in Brazil) and Nheengatu (spoken in the Amazon). Motorola remains committed to our mission of inclusion and cultural preservation, leveraging technology to bridge linguistic divides and foster a more diverse and interconnected world. To access the full data sets for each of our digitized endangered Indigenous languages, please visit: https://www.motorola.com/us/about/endangered-indigenous-languages-data-set.

Legal Disclaimers

Certain features, functionality and product specifications may be network dependent and subject to additional terms, conditions, and charges. All are subject to change without notice. MOTOROLA, the Stylized M Logo, MOTO and the MOTO family of marks are trademarks of Motorola Trademark Holdings, LLC. ©2024 Motorola Mobility LLC. All rights reserved.

About Motorola & Lenovo

Lenovo is a US$57 billion revenue global technology powerhouse, ranked #217 in the Fortune Global 500, and serving millions of customers every day in 180 markets. Focused on a bold vision to deliver Smarter Technology for All, Lenovo has built on its success as the world’s largest PC company with a pocket-to cloud portfolio of AI-enabled, AI-ready, and AI-optimized devices (PCs, workstations, smartphones, tablets), infrastructure (server, storage, edge, high performance computing and software defined infrastructure), software, solutions, and services. Lenovo’s continued investment in world-changing innovation is building a more equitable, trustworthy, and smarter future for everyone, everywhere. Lenovo is listed on the Hong Kong stock exchange under Lenovo Group Limited (HKSE: 992) (ADR: LNVGY). To find out more visit https://www.lenovo.com, and read about the latest news via our StoryHub. Motorola Mobility LLC was acquired by Lenovo Group Holdings in 2014. Motorola Mobility is a wholly owned subsidiary of Lenovo, and is responsible for designing and manufacturing all Moto and Motorola branded mobile handsets and solutions. To find out more visit https://www.lenovo.com, and read about the latest news via our StoryHub and Motorola Global Blog.

About Lenovo Foundation

Lenovo Foundation is the charitable and philanthropic arm of Lenovo, a US$57 billion revenue global technology powerhouse, ranked #217 in the Fortune Global 500, and serving millions of customers every day in 180 markets. Focused on a bold vision to deliver Smarter Technology for All, Lenovo has built on its success as the world’s largest PC company with a pocket-to cloud portfolio of AI-enabled, AI-ready, and AI-optimized devices (PCs, workstations, smartphones, tablets), infrastructure (server, storage, edge, high performance computing and software defined infrastructure), software, solutions, and services. Lenovo’s continued investment in world-changing innovation is building a more equitable, trustworthy, and smarter future for everyone, everywhere. Lenovo is listed on the Hong Kong stock exchange under Lenovo Group Limited (HKSE: 992) (ADR: LNVGY). To find out more visit https://www.lenovo.com, and read about the latest news via our StoryHub.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240606632567/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Compass Pathways Announces FDA Acceptance of IND Application for PTSD and Hosts Webinar on PTSD and TRD7.1.2026 12:30:00 CET | Press release

FDA Accepts Investigational New Drug (IND) Application for COMP360 for the treatment of post-traumatic stress disorder (PTSD), enabling initiation of late-stage trialCompass continues to advance commercial preparations to be launch-ready by the end of the year for COMP360 for treatment-resistant depression (TRD)Management will host webinar with KOL and industry leaders to discuss PTSD clinical trial and commercial preparations for TRD from 10:00-11:30 am ET on January 7th Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for COMP360, enabling the initiation of a late-stage clinical trial in patients with PTSD. Compass management, along with KOL and industry leaders, will host a webinar today to discuss the company’s clinical trial plans for PTSD, as well as commercial preparations f

Stallergenes Greer Expands Venom Immunotherapy Production Capacity With Acquisition of Entomon s.r.l.7.1.2026 11:07:00 CET | Press release

Stallergenes Greer, a global leader in allergy therapeutics, today announced that it has entered into an agreement to acquire Entomon s.r.l., an Italian company specialising in the production of certified stinging-insect venom extracts, notably of the Hymenoptera order, used for the manufacture of diagnostic preparations and Venom Immunotherapy (VIT). The transaction is expected to close by the end of January. Entomon, currently recognised as the only company in Europe capable of extracting pure venom from Hymenoptera insects, produces pharmaceutical-grade insect venom using proprietary techniques (Entomon Capillary Extracted Venom®) for medical use. Through this acquisition, Stallergenes Greer bolsters its venom manufacturing capabilities and supply of raw materials for life-saving VIT treatments, whilst safeguarding patient care continuity. Hymenoptera venom allergy is the most common trigger of severe anaphylaxis in adults1. According to the EAACI guidelines on venom immunotherapy,

ARIS Announces New CEO to Lead Agentic AI-led Strategy7.1.2026 10:00:00 CET | Press release

CEO Appointment ARIS, a global leader in process intelligence and transformation software, today announced the appointment of Guillaume Bacuvier as Chief Executive Officer. Guillaume will lead ARIS through its next phase of growth as a fully standalone company, accelerating its evolution from a market leader in Process Intelligence into a foundational platform for enterprises deploying and governing Agentic AI. Guillaume brings deep international leadership experience across technology, data, and software-enabled businesses, with a proven track record of scaling global platforms and leading complex organisations. After starting as a strategic consultant at Booz Allen Hamilton, Guillaume spent over a decade at Google, rising to Vice President in EMEA where he built and scaled some of Google’s largest data-driven businesses in Europe and held P&L responsibility across multiple countries. In the last decade, Guillaume has served as CEO of multi-continent, data-centric companies including

I Squared Capital Acquires Ramudden Global, a Leader in Traffic Management and Infrastructure Safety7.1.2026 09:00:00 CET | Press release

Acquisition will accelerate Ramudden’s ambitious growth plan across North America and Europe supported by strong infrastructure spending tailwinds I Squared Capital, a leading global infrastructure investment manager, today announced that, through its flagship fund, it has agreed to acquire Ramudden Global, from funds advised by Triton Partners (“Triton”), a leading European mid-market sector-specialist investor. Ramudden Global is a leading international provider of traffic management and infrastructure safety services supporting the maintenance and upgrade of essential transport and utility networks. The company operates more than 190 depots across 13 countries in Europe and North America delivering mission-critical services that help to ensure safety, regulatory compliance and continuity of service across road, utility and broader infrastructure works. This investment underscores I Squared Capital’s commitment to investing in essential, regulated, infrastructure businesses that unde

RoslinCT and BOOST Pharma Announce Strategic Manufacturing Agreement to Advance Cell Therapy for Infants with Osteogenesis Imperfecta7.1.2026 09:00:00 CET | Press release

RoslinCT, a global contract development and manufacturing organization (CDMO) specializing in advanced cell therapies, and BOOST Pharma, a clinical-stage biotechnology company developing first-in-class cell therapies for rare paediatric skeletal diseases, today announced a strategic manufacturing partnership to support the development of BOOST Pharma’s cell therapy, BT-101, for the treatment of infants with Osteogenesis Imperfecta (OI), also known as brittle bone disease. Under the service agreement, BOOST Pharma has transferred its manufacturing process to RoslinCT’s state-of-the-art facilities in Edinburgh, Scotland. The partnership will progress toward GMP manufacturing of starting materials and clinical drug product, supporting Phase III clinical development of BT-101. The therapy is an allogeneic mesenchymal stem cell (MSC) product designed to address the underlying cause of OI at the earliest stages of life. BOOST Pharma was founded on pioneering science originating from Karolins

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye